(Q34074994)

30 July 2017

1 reference

title

Novel agents for the therapy of varicella-zoster virus infections (English)

1 reference

30 July 2017

Snoeck R

1

1 reference

30 July 2017

Andrei G

series ordinal

2

1 reference

30 July 2017

De Clercq E

series ordinal

3

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 August 2000

1 reference

Expert Opinion on Investigational Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

9

1 reference

30 July 2017

issue

8

1 reference

30 July 2017

page(s)

1743-1751

1 reference

Virus infections in bone marrow transplant recipients: a three year prospective study

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Fatal varicella-zoster virus meningoradiculitis without skin involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Meningoradiculoneuritis due to acyclovir-resistant varicella zoster virus in an acquired immune deficiency syndrome patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Myelitis due to varicella-zoster virus in two patients with AIDS: successful treatment with acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Acyclovir-resistant varicella zoster responsive to foscarnet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Analysis of mutations in the thymidine kinase genes of drug-resistant varicella-zoster virus populations using the polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Foscarnet Therapy in Five Patients with AIDS and Acyclovir-resistant Varicella-Zoster Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

A controlled trial of acyclovir for chickenpox in normal children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Treatment with acyclovir of varicella pneumonia in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

The management of postherpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Postherpetic neuralgia in immunocompetent elderly people

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Acyclovir Halts Progression of Herpes Zoster in Immunocompromised Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine treatment of severe herpes zoster in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Oral BVDU treatment of varicella and zoster in children with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Acyclovir: A Decade Later

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Antiviral therapy of acute herpes zoster in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Famciclovir for the Treatment of Acute Herpes Zoster: Effects on Acute Disease and Postherpetic Neuralgia: A Randomized, Double-Blind, Placebo-Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

A novel selective broad-spectrum anti-DNA virus agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

Clinical uses of cidofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.8.1743

10.1517/13543784.9.8.1743

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference